Literature DB >> 2852574

Laboratory studies of acute varicella and varicella immune status.

H H Balfour1, C K Edelman, C L Dirksen, D R Palermo, C S Suarez, J Kelly, J T Kentala, D D Crane.   

Abstract

We evaluated varicella-zoster virus (VZV) culture and serum antibody methods utilizing specimens from 620 children enrolled in protocols for prevention or treatment of varicella and samples routinely submitted to the Clinical Virology Laboratory. In a foreskin fibroblast tube culture system, we initially isolated VZV from only 29 (51%) of 57 children cultured on the first day of varicella. After modifying the method, the proportion of culture-positive children increased significantly to 36 (80%) of 45 (p less than 0.005 by corrected X2), and the median days-to-positivity were significantly shortened from 5.6 to 3.8 days (p less than 0.001, Wilcoxon rank-sum test). The Viran fluorescent antibody to membrane antigen (FAMA) assay was difficult to read and not reproducible. The standard FAMA was more sensitive than the Merck ELISA antibody test for detecting vaccine-induced antibody. The Whittaker ELISA did not detect vaccine-induced antibody but was comparable to FAMA for immune status testing (sensitivity, 95%; specificity, 92%) and for diagnosis of acute varicella.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2852574     DOI: 10.1016/0732-8893(88)90034-x

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  6 in total

1.  Comparative study of the standard fluorescent antibody to membrane antigen (FAMA) assay and a flow cytometry-adapted FAMA assay to assess immunity to varicella-zoster virus.

Authors:  M M Lafer; L Y Weckx; M I de Moraes-Pinto; A Garretson; S P Steinberg; A A Gershon; P S LaRussa
Journal:  Clin Vaccine Immunol       Date:  2011-05-25

2.  Acyclovir treatment for varicella does not lower gpI and IE-62 (p170) antibody responses to varicella-zoster virus in normal children.

Authors:  J A Englund; A M Arvin; H H Balfour
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

3.  Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen.

Authors:  A Sauerbrei; P Wutzler
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

4.  Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay.

Authors:  P A C Maple; J Gray; J Breuer; G Kafatos; S Parker; D Brown
Journal:  Clin Vaccine Immunol       Date:  2006-02

5.  Evaluation of a commercial glycoprotein enzyme-linked immunosorbent assay for measuring vaccine immunity to varicella.

Authors:  Yun Hwa Kim; Ji Young Hwang; Hye Min Shim; Eunsil Lee; Songyong Park; Hosun Park
Journal:  Yonsei Med J       Date:  2014-03       Impact factor: 2.759

6.  Study of susceptibility towards varicella by screening for the presence of IgG antibodies among nursing and medical students of a tertiary care teaching hospital in pune, India.

Authors:  Samir A Singru; Vijay W Tilak; N Gandham; Jitendra S Bhawalkar; Sudhir L Jadhav; Harshal T Pandve
Journal:  J Glob Infect Dis       Date:  2011-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.